文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

哮喘与心血管疾病:共同药物相互作用的应对策略。

Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences.

机构信息

Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome 'Tor Vergata', Rome, Italy.

Institute of Pharmaceutical Science, King's College London, London, UK.

出版信息

Drugs. 2024 Oct;84(10):1251-1273. doi: 10.1007/s40265-024-02086-5. Epub 2024 Sep 26.


DOI:10.1007/s40265-024-02086-5
PMID:39327397
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11512905/
Abstract

Asthma and cardiovascular disease (CVD) often co-exist. When a patient has both conditions, management requires an approach that addresses the unique challenges of each condition separately, while also considering their potential interactions. However, specific guidance on the management of asthma in patients with CVD and on the management of CVD in patients with asthma is still lacking. Nevertheless, health care providers need to adopt a comprehensive approach that includes both respiratory and CVD health. The management of CVD in patients with asthma requires a delicate balance between controlling respiratory symptoms and minimising potential cardiovascular (CV) risks. In the absence of specific guidelines for the management of patients with both conditions, the most prudent approach would be to follow established guidelines for each condition independently. Careful selection of asthma medications is essential to avoid exacerbation of CV symptoms. In addition, optimal management of CV risk factors is essential. However, close monitoring of these patients is important as there is evidence that some asthma medications may have adverse effects on CVD and, conversely, that some CVD medications may worsen asthma symptoms. On the other hand, there is also increasing evidence of the potential beneficial effects of asthma medications on CVD and, conversely, that some CVD medications may reduce the severity of asthma symptoms. We aim to elucidate the potential risks and benefits associated with the use of asthma medications in patients with CVD, and the potential pulmonary risks and benefits for patients with asthma who are prescribed CVD medications.

摘要

哮喘和心血管疾病(CVD)常常同时存在。当患者同时患有这两种疾病时,管理需要采用一种分别针对每种疾病独特挑战的方法,同时考虑它们可能的相互作用。然而,关于心血管疾病患者中哮喘的管理以及哮喘患者中 CVD 的管理的具体指导仍然缺乏。尽管如此,医疗保健提供者需要采取一种综合的方法,包括呼吸和心血管健康。在哮喘患者中管理 CVD 需要在控制呼吸系统症状和最小化潜在心血管(CV)风险之间取得微妙的平衡。在缺乏针对同时患有这两种疾病的患者的管理指南的情况下,最谨慎的方法是独立遵循每种疾病的既定指南。仔细选择哮喘药物对于避免 CV 症状恶化至关重要。此外,还需要优化管理 CV 危险因素。然而,密切监测这些患者非常重要,因为有证据表明一些哮喘药物可能对 CVD 有不良影响,反之亦然,一些 CVD 药物可能会加重哮喘症状。另一方面,也有越来越多的证据表明哮喘药物对 CVD 可能有潜在的有益影响,反之亦然,一些 CVD 药物可能会减轻哮喘症状的严重程度。我们旨在阐明在 CVD 患者中使用哮喘药物相关的潜在风险和益处,以及在被处方 CVD 药物的哮喘患者中可能的肺部风险和益处。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6cc/11512905/8f7ab9227cc2/40265_2024_2086_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6cc/11512905/5746c649f74f/40265_2024_2086_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6cc/11512905/4849ad93be52/40265_2024_2086_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6cc/11512905/98e84ea7920a/40265_2024_2086_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6cc/11512905/a9d6c75ca917/40265_2024_2086_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6cc/11512905/8f7ab9227cc2/40265_2024_2086_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6cc/11512905/5746c649f74f/40265_2024_2086_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6cc/11512905/4849ad93be52/40265_2024_2086_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6cc/11512905/98e84ea7920a/40265_2024_2086_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6cc/11512905/a9d6c75ca917/40265_2024_2086_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6cc/11512905/8f7ab9227cc2/40265_2024_2086_Fig5_HTML.jpg

相似文献

[1]
Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences.

Drugs. 2024-10

[2]
[Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].

Zhonghua Jie He He Hu Xi Za Zhi. 2024-2-12

[3]
Overcoming gaps in the management of asthma in older patients: new insights.

Drugs Aging. 2005

[4]
Acute severe asthma: new approaches to assessment and treatment.

Drugs. 2009

[5]
Cardiovascular Considerations and Implications for Treatment in Psoriasis: An Updated Review.

Vasc Health Risk Manag. 2024

[6]
[Guidelines for the prevention and management of bronchial asthma (2024 edition)].

Zhonghua Jie He He Hu Xi Za Zhi. 2025-3-12

[7]
Cardiovascular disease in asthma patients: From mechanisms to therapeutic implications.

Kardiol Pol. 2023

[8]
Safety of asthma and allergy medications in pregnancy.

Immunol Allergy Clin North Am. 2006-2

[9]
Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007.

J Allergy Clin Immunol. 2007-11

[10]
Polypharmacy in older patients with asthma: hidden risks and opportunities for improvement.

Expert Rev Respir Med. 2024-12

引用本文的文献

[1]
Equine Asthma in a Comparative Perspective: Cardiovascular and Neurological Manifestations of Asthma Across Different Species.

Animals (Basel). 2025-8-12

[2]
The Effect of Comorbidities on Asthma-Related Outcomes Over a Two-Year Period: A Prospective Analysis of Swiss Severe Asthma Registry (SSAR).

J Asthma Allergy. 2025-7-15

[3]
Association and risk factors analysis of FeNO and CRP in bronchial asthma combined with obstructive sleep apnea.

Front Med (Lausanne). 2025-6-30

[4]
LASSO regression and Boruta algorithm to explore the relationship between neutrophil percentage to albumin ratio and asthma: results from the NHANES 2001 to 2018.

Clin Exp Med. 2025-5-10

本文引用的文献

[1]
Allergic asthma is a risk factor for human cardiovascular diseases.

Nat Cardiovasc Res. 2022-5

[2]
Identification of a non-canonical chemokine-receptor pathway suppressing regulatory T cells to drive atherosclerosis.

Nat Cardiovasc Res. 2024-2-1

[3]
Association between asthma and cardiovascular diseases: A longitudinal follow-up study using a national health screening cohort.

World Allergy Organ J. 2024-5-30

[4]
An overview of the efficacy and safety of β-adrenoceptor antagonists for the treatment of chronic obstructive pulmonary disease.

Expert Opin Drug Saf. 2024-7

[5]
Statin administration or blocking PCSK9 alleviates airway hyperresponsiveness and lung fibrosis in high-fat diet-induced obese mice.

Respir Res. 2024-5-18

[6]
Association between lipid-lowering drugs and allergic diseases: A Mendelian randomization study.

World Allergy Organ J. 2024-4-10

[7]
Montelukast, an available and safe anti-asthmatic drug, prevents maladaptive remodelling and maintains cardiac functionality following myocardial infarction.

Sci Rep. 2024-2-9

[8]
Cardiovascular Events with the Use of Long-Acting Muscarinic Receptor Antagonists: An Analysis of the FAERS Database 2020-2023.

Lung. 2024-4

[9]
Long-Term Efficacy and Tolerability of PCSK9 Targeted Therapy: A Review of the Literature.

Drugs. 2024-2

[10]
Asthma and incident coronary heart disease: an observational and Mendelian randomisation study.

Eur Respir J. 2023-11

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索